PTC Therapeutics has abandoned its latest attempt to secure FDA approval for Duchenne muscular dystrophy (DMD) treatment Translarna, after the FDA said it was unlikely to approve the drug based on the ...
PTC Inc. is warning of a critical vulnerability in Windchill and FlexPLM, widely used product lifecycle management (PLM) solutions, that could allow remote code execution. The security issue, ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
PTC Therapeutics is transitioning its growth engine from legacy drugs to new launches like Sephience, targeting rare genetic diseases with high unmet need. Pipeline catalysts, notably Votoplam for ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
With the writing apparently on the wall, PTC Therapeutics has called off its latest bid for FDA approval of its Duchenne muscular dystrophy (DMD) drug Translarna. Late Thursday, PTC revealed that it ...
PTC Inc. (PTC) came out with quarterly earnings of $1.64 per share, beating the Zacks Consensus Estimate of $1.22 per share. This compares to earnings of $0.98 per share a year ago. These figures are ...
April 30 - Industrial software maker PTC (PTC.O), opens new tab raised its annual revenue forecast and beat Wall Street estimates for second-quarter revenue on Wednesday, driven by resilient demand ...
Feb 5 (Reuters) - PTC (PTC.O), opens new tab cut its full-year revenue and adjusted earnings forecasts on Wednesday amid increasing competition and fears over President Donald Trump's tariff policy, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results